论文部分内容阅读
丙型肝炎病毒(Hepatitis C virus infection,HCV)感染在肾脏疾病患者中并不少见,尤其是终末期肾病进行透析的患者中,感染率明显高于一般人群。两种疾病互相影响,导致疾病进展,影响患者生存质量。抗HCV治疗在我国现有治疗条件下仍以干扰素联合利巴韦林(ribavirin,RBV)为主要治疗方案,在肾功能不全患者不论干扰素还是RBV均需要进行剂量调整。未来直接抗病毒药物(direct antiviral drugs,DAAs)将是这类患者的主要治疗方案。现阶段HCV感染在终末期肾病和肾移植患者中的治疗仍面临挑战。
Hepatitis C virus infection (HCV) infection is not uncommon in patients with kidney disease, especially in patients with end-stage renal disease undergoing dialysis, the infection rate was significantly higher than the general population. Two diseases affect each other, leading to disease progression, affecting the quality of life of patients. Anti-HCV treatment is still the main treatment of ribavirin (ribavirin, ribavirin, ribavirin (RBV) under the current treatment conditions in our country, in patients with renal insufficiency regardless of interferon or RBV dose adjustment needed. The future of direct antiviral drugs (DAAs) will be the primary treatment option for these patients. At this stage of the treatment of HCV infection in patients with end-stage renal disease and renal transplantation are still facing challenges.